Form 4: Anika Therapeutics Director's Equity Transactions

Anika Therapeutics Director Cheryl R. Blanchard reported the vesting and tax-related disposition of restricted stock units and performance-based units.

Summary

• On March 14, 2026, Director Cheryl R. Blanchard acquired 24,519 shares of Anika Therapeutics common stock from the vesting of restricted stock units (RSUs), representing the first installment of an RSU award granted on March 14, 2025.
• On March 14, 2026, Director Cheryl R. Blanchard also acquired 24,520 shares of Anika Therapeutics common stock from the vesting of performance-based phantom RSUs (PSUs), representing the first installment of a PSU award granted on March 14, 2025.
• On March 14, 2026, 14,728 shares of common stock were retained by Anika Therapeutics to satisfy tax withholding obligations related to the vested RSUs and PSUs, at a price of $14.2 per share.
• On March 15, 2026, Director Cheryl R. Blanchard acquired 25,131 shares of Anika Therapeutics common stock from the vesting of restricted stock units (RSUs), representing the second installment of an RSU award granted on March 15, 2024.
• On March 15, 2026, 12,104 shares of common stock were retained by Anika Therapeutics to satisfy tax withholding obligations related to the vested RSUs, at a price of $14.2 per share.
• Following these reported transactions, Director Blanchard directly beneficially owns 258,788 shares of common stock.
• Director Blanchard also indirectly owns 11,742 shares of common stock through The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, for which she is a beneficiary and sole trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard equity compensation vesting and tax management for a director, with no new material information regarding the company's operational or financial performance.

Positives

• Director Cheryl R. Blanchard received 24,519 shares from the vesting of RSUs, indicating the fulfillment of equity compensation.
• Director Cheryl R. Blanchard received 24,520 shares from the vesting of performance-based PSUs, suggesting the achievement of pre-established performance and strategic targets.
• Director Cheryl R. Blanchard received an additional 25,131 shares from the vesting of RSUs, further increasing her direct ownership in the company.

Negatives

• A total of 14,728 shares of common stock were disposed of on March 14, 2026, to cover tax withholding obligations related to vested equity awards.
• An additional 12,104 shares of common stock were disposed of on March 15, 2026, to cover tax withholding obligations related to vested equity awards.

Future Outlook

The filing indicates future vesting installments for the RSU and PSU awards granted to Director Blanchard, implying continued equity compensation over the coming years.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, reflecting common equity compensation structures in the biotech and medical device industry. The vesting of RSUs and PSUs is a standard mechanism to align executive and director interests with shareholder value over the long term.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in director ownership, aligning director interests with company performance through equity compensation.
• Director Cheryl R. Blanchard: The vesting of RSUs and PSUs increases her direct beneficial ownership in Anika Therapeutics, while tax-related dispositions reduce the net shares received.

Next Steps

• Future vesting installments of the RSU award granted on March 14, 2025, will occur annually.
• Future vesting installments of the PSU award granted on March 14, 2025, will occur annually, contingent on performance and strategic targets.
• The final vesting installment of the RSU award granted on March 15, 2024, is expected in March 2027.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to equity compensation vesting and tax withholding. It does not provide new fundamental information about Anika Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are pre-scheduled and expected, thus having a neutral impact on the stock's valuation.

Keywords

Anika Therapeutics, ANIK, Form 4, Insider Transaction, Restricted Stock Unit, Performance Share Unit, Equity Compensation, Director Ownership, Stock Vesting, Tax Withholding